Time to Stop Using Ineffective Covid-19 Drugs-Reference-Cited by-同舟云学术

Time to Stop Using Ineffective Covid-19 Drugs

Published:2022-08-18 Issue:7 Volume:387 Page:654-655
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Abdool Karim Salim S.¹,Devnarain Nikita¹

Affiliation:

1. From the Centre for the AIDS Programme of Research in South Africa, Durban (S.S.A.K., N.D.); and the Department of Epidemiology, Mailman School of Public Health, Columbia University, New York (S.S.A.K.).

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMe2209017

Reference8 articles.

1. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19

2. Fluvoxamine in Nonhospitalized Patients With Acute COVID-19 Infection and the Lack of Efficacy in Reducing Rates of Hospitalization, Mechanical Ventilation, and Mortality in Placebo-Controlled Trials: A Systematic Review and Meta-Analysis

3. Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients

4. The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID‐19

5. Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mismanagement of SARS-CoV-2 Infection Pre Hospitalisation during the Omicron Era: Antibiotics and Steroids Instead of Early Antivirals;Viruses;2024-06-22

2. Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections;Viruses;2024-04-22

3. Mechanisms of antiviral action and toxicities of ipecac alkaloids: Emetine and dehydroemetine exhibit anti-coronaviral activities at non-cardiotoxic concentrations;Virus Research;2024-03

4. Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population;International Journal of Immunopathology and Pharmacology;2024-01

5. Even one dose of tocilizumab could hinder bad prognosis of cytokines storm in COVID-19 patients;Cytokine;2024-01